RABENIS
DSR
For the use only of a Registered
Medical Practitioner or Hospital or a Laboratory
Abbreviated Prescribing information
for RABENIS DSR (Rabeprazole sodium 20 mg and Domperidone 30 mg sustained
release capsules)
[Please refer the complete
prescribing information available at www.macnispharma.com ]
PHARMACOLOGICAL
PROPERTIES: Rabeprazole belongs to a class of antisecretory compounds
(substituted benzimidazole proton-pump inhibitors) which suppress gastric acid
secretion. Domperidone is a unique gastrokinetic and antiemetic drug.
INDICATION:
For the treatment of Gastroesophageal reflux disease (GERD) that is not treated
adequately with PPIs or H2 Receptor Antagonist (H2RA) alone.
DOSAGE
AND ADMINISTRATION: One capsule once daily preferably before meal.
CONTRAINDICATION:
Patients with known hypersensitivity to rabeprazole sodium, substituted
benzimidazoles, domperidone or to any excipient used in the formulation. In
patients with prolactinoma, gastro-intestinal haemorrhage, mechanical
obstruction or perforation, severe hepatic impairment, prolonged cardiac
conduction intervals (particularly QTc), significant electrolyte disturbances
or underlying cardiac diseases and in patients receiving potent CYP3A4 inhibitors
and QT-prolonging drugs.
WARNINGS
& PRECAUTIONS: Symptomatic response to therapy with rabeprazole does not
preclude the presence of gastric malignancy. Monitor for increases in INR and
prothrombin time when used with warfarin. Risk of acute interstitial nephritis,
Clostridium difficile associated diarrhoea, prolongation of QT interval and
neurological side effects in young children. On prolonged therapy risk of
cyanocobalamin (vitamin B-12) Deficiency, bone fracture and hypomagnesemia.
Dose reduction required in patients with renal impairment.
DRUG
INTERACTIONS: Interact with QT-prolonging drugs (for ex. erythromycin,
levofloxacin, cisapride etc.), CYP3A4 inhibitors (for ex. systemic azole
antifungals, diltiazem etc), bradycardia and hypokalaemia-inducing drugs (for
ex. azithromycin and roxithromycin) warfarin, cyclosporine, ketoconazole, iron
salts, digoxin, mycophenolate mofetil, atazanavir and methotrexate when used
concomitantly.
ADVERSE
REACTIONS: Pain, pharyngitis, flatulence, infection, constipation, abdominal
pain, diarrhoea, headache, sudden cardiac death, coma, jaundice, rhabdomyolysis,
anaphylaxis, severe dermatologic reactions, including toxic epidermal
necrolysis (some fatal), Stevens-Johnson syndrome, interstitial pneumonia,
convulsion, extrapyramidal disorder, ventricular arrhythmias, Torsade de
Pointes, urinary retention, gynaecomastia and amenorrhoea.
MARKETED
BY:
MACNIS PHARMACEUTICALS
J3/31 A-3,3rd
Floor,Khiri Extension.
Malviya Nagar,New Delhi-17
Visit us at: www.macnispharma.com
Reach us at: info@macnispharma.com